explore -WSS

explore

author：focus 2025-09-28 20:33:06 - browse：764

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： MultiPlan and major insurers sued for alleged medical price

knowledge

entertainment

WSS

Melinda French Gates resigns from Gates Foundation

Key Senate committee drafts bipartisan bill to stem drug shortages

Why does health care cost so much? A reading guide

A new study sees potential in DNA sequencing of infants

Melinda French Gates resigns from Gates Foundation

Bulgari apologizes to China for listing Taiwan as a country after online backlash

focus

explore

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why 40% Americans with Parkinson’s don’t see a neurologist

BioMarin wins approval for gene therapy to treat hemophilia A

Leqembi, other new Alzheimer’s drugs require better biomarkers

Trump demands the U.S. pay no more for drugs than other countries … again

Cue Health's Covid

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New research casts further doubt on a common procedure used with IVF

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why rehabilitation engineers need to center patients in their research

hotspot

UnitedHealth financials solid despite Change Healthcare cyberattack

H5N1 bird flu virus started spreading in cows in Texas in December

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Melinda French Gates resigns from Gates Foundation

Melinda French Gates resigns from Gates Foundation

H5N1 bird flu virus started spreading in cows in Texas in December

knowledge

entertainment

leisure time

hotspot